TRAF2 Gene

📖 Wiki Page

gene1733 wordssynced 2026-04-02

TRAF2 Gene

Introduction

...

TRAF2 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TRAF2 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>TRAF2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>TNF Receptor Associated Factor 2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>9q34.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>7186</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>601985</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000126933</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9UAV6</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>E3 ubiquitin ligase (TRAF family)</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>TRAP, TNF-R2-associated factor, MORT1-associated protein</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Rheumatoid Arthritis, Cancer</td>
</tr>
<tr>
<td class="label">Mediator</td>
<td>Function</td>
</tr>
<tr>
<td class="label">TNF-α</td>
<td>Pro-inflammatory cytokine</td>
</tr>
<tr>
<td class="label">IL-1β</td>
<td>Inflammatory cytokine</td>
</tr>
<tr>
<td class="label">IL-6</td>
<td>Acute phase response</td>
</tr>
<tr>
<td class="label">Chemokines (CCL2, CXCL8)</td>
<td>Immune cell recruitment</td>
</tr>
<tr>
<td class="label">COX-2</td>
<td>Prostaglandin synthesis</td>
</tr>
<tr>
<td class="label">iNOS</td>
<td>Nitric oxide production</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">TNFR1</td>
<td>Receptor binding</td>
</tr>
<tr>
<td class="label">TNFR2</td>
<td>Receptor binding</td>
</tr>
<tr>
<td class="label">CD40</td>
<td>Receptor binding</td>
</tr>
<tr>
<td class="label">TRAF1</td>
<td>Heterotrimer</td>
</tr>
<tr>
<td class="label">TRAF3</td>
<td>Heterotrimer</td>
</tr>
<tr>
<td class="label">c-IAP1/2</td>
<td>Ubiquitination</td>
</tr>
<tr>
<td class="label">NEMO/IKKγ</td>
<td>Signal transduction</td>
</tr>
<tr>
<td class="label">RIPK1</td>
<td>Kinase binding</td>
</tr>
<tr>
<td class="label">TRADD</td>
<td>Adaptor binding</td>
</tr>
<tr>
<td class="label">A20</td>
<td>Negative regulation</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Neurons</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Microglia</td>
<td>High, increases with activation</td>
</tr>
<tr>
<td class="label">Astrocytes</td>
<td>Constitutive, increased in reactive gliosis</td>
</tr>
<tr>
<td class="label">Oligodendrocytes</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Endothelial cells</td>
<td>Moderate</td>
</tr>
</table>

The TRAF2 gene (TNF Receptor Associated Factor 2) encodes a critical E3 ubiquitin ligase that serves as a central adaptor protein in TNF receptor signaling pathways. Located at chromosome 9q34.3, TRAF2 plays essential roles in regulating NF-κB signaling, apoptosis, cellular stress responses, and inflammatory cascades that are fundamental to both normal immune function and the pathogenesis of neurodegenerative diseases[@arch1998][@bradley2001]. Research has increasingly implicated TRAF2-mediated signaling in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and other neurological disorders, making it an important therapeutic target. The protein functions as both an adaptor molecule and an E3 ubiquitin ligase, enabling it to orchestrate complex signaling networks that determine cell survival, death, and inflammatory responses in the brain.

Gene Overview

Protein Structure and Function

Domain Architecture

The TRAF2 protein contains several distinct structural domains that enable its diverse functions:

RING domain (N-terminus): The RING finger domain confers E3 ubiquitin ligase activity. This domain catalyzes the transfer of ubiquitin molecules to target proteins, particularly RIPK1 and other signaling intermediates. The RING domain is essential for the pro-survival functions of TRAF2 in TNFR1 signaling.

Zinc fingers: Multiple zinc finger motifs (typically 5-7) provide protein-protein interaction surfaces. These zinc fingers mediate binding to various signaling proteins and contribute to the adaptor function of TRAF2.

Coiled-coil domain (TRAF-N domain): This trimeric coiled-coil region mediates receptor binding and interactions with other TRAF proteins. It allows TRAF2 to form homotypic and heterotypic complexes with TRAF1, TRAF3, and other TRAF family members.

TRAF domain (C-terminus): The conserved TRAF domain enables trimerization and is critical for downstream signaling. This domain interacts with TNFR2, CD40, and other receptors, as well as with negative regulators.

The overall architecture allows TRAF2 to function as a molecular scaffold, assembling signaling complexes while simultaneously catalyzing ubiquitin chain synthesis.

Enzymatic Activity

TRAF2 exhibits two major enzymatic functions:

E3 Ubiquitin Ligase Activity

TRAF2 synthesizes various types of ubiquitin chains:

Lys63-linked polyubiquitin chains: Primarily pro-inflammatory signaling, activates NF-κB and MAPK pathways
Lys48-linked polyubiquitin chains: Target proteins for proteasomal degradation
Linear polyubiquitin chains: Activate NF-κB in a non-canonical manner

The ubiquitin chains generated by TRAF2 serve as signaling platforms that recruit downstream effectors bearing ubiquitin-binding domains.

Scaffold Function

Beyond its enzymatic activity, TRAF2 serves as a critical adaptor:

Brings together TNFR signaling components
Facilitates protein-protein interactions
Coordinates signal transduction complexes

Role in Neurodegeneration

Alzheimer's Disease

TRAF2-mediated NF-κB signaling is chronically activated in Alzheimer's disease, contributing to disease pathogenesis through multiple mechanisms[@kaltschmidt2005][@chen2012]:

Amyloid-Beta-Induced Inflammation

Amyloid-beta (Aβ) peptides activate NF-κB signaling through TRAF2-dependent pathways:

Aβ binds to RAGE (Receptor for Advanced Glycation End-products) and activates downstream TRAF2/NF-κB signaling
Microglial cells show increased TRAF2 expression in response to Aβ
This creates a feed-forward inflammatory loop that drives chronic neuroinflammation

Neuronal Survival vs Death

The role of TRAF2/NF-κB in neurons is complex:

Early disease: NF-κB activation can be protective, promoting expression of anti-apoptotic proteins
Late disease: Chronic NF-κB activation becomes detrimental, promoting inflammatory gene expression
The balance between canonical and non-canonical NF-κB pathways determines neuronal outcomes

Glial Activation

TRAF2-mediated signaling contributes to reactive gliosis:

Astrocyte and microglial activation in response to Aβ
Production of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6)
Sustained inflammatory environment that drives disease progression

Tau Pathology

TRAF2 intersects with tau pathology through several mechanisms:

NF-κB can regulate tau-phosphorylating kinases (GSK3β, CDK5)
Inflammatory signaling may accelerate tau aggregation
TRAF2 levels correlate with tau pathology severity in AD brains[@mondragon2019]

Parkinson's Disease

In Parkinson's disease, TRAF2/NF-κB signaling contributes to dopaminergic neuron loss[@ghosh2019][@deleidi2010]:

Dopaminergic Neuron Vulnerability

Inflammatory signaling exacerbates the inherent vulnerability of dopaminergic neurons in the substantia nigra
TRAF2-mediated NF-κB activation promotes expression of pro-apoptotic proteins
Mitochondrial dysfunction and ER stress converge on TRAF2 signaling

Microglial Activation

Sustained TRAF2/NF-κB activation in microglia within the substantia nigra
Production of neurotoxic inflammatory mediators
Chronic activation creates a toxic microenvironment for neurons

Alpha-Synuclein Pathology

TRAF2 interacts with α-synuclein pathology:

Inflammatory responses may accelerate α-synuclein aggregation
α-Synuclein can activate NF-κB through TRAF2-dependent pathways
This creates a pathogenic loop between protein aggregation and inflammation

Amyotrophic Lateral Sclerosis (ALS)

TRAF2 dysregulation has been implicated in ALS[@wu2017]:

Mutations in ALS-related genes (SOD1, FUS, TARDBP) affect inflammatory signaling
TRAF2-mediated NF-κB activation in motor neurons
Glial cell activation and inflammatory-mediated motor neuron death

Neuroinflammation Mechanisms

TRAF2-mediated NF-κB activation drives production of multiple inflammatory mediators[@glass2010]:

Signaling Pathways

Canonical NF-κB Pathway

TRAF2 is essential for canonical (classical) NF-κB signaling:

TNFR1 activation: TNF-α binds TNFR1

TRADD recruitment: Adaptor protein recruited to receptor

TRAF2 recruitment: TRAF2 binds to TRADD through its TRAF domain

RIPK1 ubiquitination: TRAF2 ubiquitinates RIPK1 with Lys63-linked chains

NEMO recruitment: NEMO (IKKγ) binds ubiquitinated RIPK1

IKK activation: IKKβ phosphorylates IκBα

NF-κB activation: Released NF-κB translocates to nucleus

Non-Canonical NF-κB Pathway

TRAF2 also plays roles in non-canonical NF-κB signaling:

Regulates NIK (NF-κB-inducing kinase) stability
Controls processing of p100 to p52
Affects lymphocyte development and function

MAPK Pathways

TRAF2 coordinates MAPK activation:

JNK activation through MAP3Ks
p38 activation in response to stress
ERK activation for cell survival

Protein Interactions

TRAF2 interacts with numerous proteins to execute its signaling functions:

Expression Pattern

TRAF2 is expressed in various brain cell types with distinct patterns:

Brain expression is influenced by:

Aging (generally increases)
Disease state (further upregulated)
Cytokine exposure (TNF-α, IL-1β)

Clinical Significance

Therapeutic Implications

Targeting TRAF2/NF-κB pathway for neurodegeneration is an active area of research[@oneill2023][@barnes2023]:

NF-κB inhibitors: At the TRAF2 level or downstream

Ubiquitination modulators: Targeting E3 ligase activity

Anti-inflammatory therapies: Broad-based approaches

Challenges

NF-κB has both protective and pathogenic roles
Systemic inhibition increases infection risk
Timing of intervention critical (early vs. late disease)

Diagnostic Potential

TRAF2 expression may serve as:

Disease progression marker
Therapeutic response indicator
Biomarker for neuroinflammation

Research Methods

Experimental Models

In vitro: Neuronal and glial cell cultures
Animal models: Transgenic AD/PD mice
Human tissue: Post-mortem brain samples
iPSC models: Patient-derived neurons

Key Techniques

Immunohistochemistry for localization
Western blot for protein levels
qPCR for gene expression
Luciferase reporter for NF-κB activity
Ubiquitination assays

Key Publications

[Arch RH, et al. TRAF proteins and modulation of immune receptor signaling (1998)](https://doi.org/10.1074/jbc.273.45.29655)

[Bradley JR, Pober JS. TNF receptor-associated factors (TRAFs) (2001)](https://doi.org/10.1038/sj.onc.1204784)

[Wajant H, et al. TNF receptor signaling (2003)](https://doi.org/10.1038/sj.cdd.4401235)

[Kaltschmidt B, et al. NF-κB in Alzheimer's disease (2005)](https://pubmed.ncbi.nlm.nih.gov/15651056/)

[Chen CH, et al. TRAF2 and TNFR signaling in neurodegeneration (2012)](https://pubmed.ncbi.nlm.nih.gov/22824041/)

[Ghosh A, et al. NF-κB in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30816544/)

[Deleidi M, et al. Neuroinflammation in Parkinson's disease (2010)](https://pubmed.ncbi.nlm.nih.gov/20429778/)

[Glass CK, et al. Mechanisms underlying inflammation in neurodegeneration (2010)](https://pubmed.ncbi.nlm.nih.gov/20303876/)

[O'Neill LA, et al. Targeting NF-κB for neuroprotection (2023)](https://doi.org/10.1038/s41573-023-00723-4)

[Barnes DE, et al. NF-κB in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36737452/)

[Matta SK, et al. TRAF2: structure and therapeutic targeting (2019)](https://pubmed.ncbi.nlm.nih.gov/31134237/)

[Hu W, et al. TRAF2 in neuronal apoptosis (2019)](https://pubmed.ncbi.nlm.nih.gov/31754922/)

[Mondragon-Rodriguez S, et al. TRAF2 in tau pathology (2019)](https://pubmed.ncbi.nlm.nih.gov/30623214/)

[Zhao J, et al. Ubiquitination and neuroprotection (2021)](https://pubmed.ncbi.nlm.nih.gov/34116899/)

[Liu Q, et al. TRAF2 and neuroinflammation in AD (2022)](https://pubmed.ncbi.nlm.nih.gov/35698199/)

External Links

[NCBI Gene: TRAF2](https://www.ncbi.nlm.nih.gov/gene/7186)
[UniProt: Q9UAV6](https://www.uniprot.org/uniprot/Q9UAV6)
[OMIM: 601985](https://www.omim.org/entry/601985)
[Ensembl: ENSG00000126933](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000126933)
[Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/)
[Allen Brain Atlas: TRAF2 expression](https://human.brain-map.org/)
[Parkinson's Progression Markers Initiative](https://ppmi-info.org/)

Last updated: 2026-03-26

References

arch1998, TRAF proteins and modulation of immune receptor signaling (1998) [1](https://doi.org/10.1074/jbc.273.45.29655)
barnes2023, NF-κB pathway in Alzheimer's disease: mechanisms and therapeutic targeting (2023)
bradley2001, TNF receptor-associated factors (TRAFs) (2001) [1](https://doi.org/10.1038/sj.onc.1204784)
chen2012, TRAF2 and TNFR signaling in neurodegeneration (2012)
deleidi2010, Development of neuroinflammation and dopaminergic neuron loss in Parkinson's disease (2010)
ghosh2019, NF-κB in Parkinson's disease: evidence and therapeutic implications (2019)
glass2010, Mechanisms underlying inflammation in neurodegeneration (2010)
hu2019, Role of TRAF2 in neuronal apoptosis and neurological disorders (2019)
kaltschmidt2005, NF-κB in Alzheimer's disease: role in pathogenesis and therapeutic opportunities (2005)
kawai2019, TLR signaling and NF-κB activation (2019)
liu2022, TRAF2 and neuroinflammation in Alzheimer's disease (2022)
matta2019, TRAF2: structure, function, and therapeutic targeting in cancer and neurodegeneration (2019)
mondragon2019, TRAF2 in tau pathology and neurodegenerative diseases (2019)
oneill2023, Targeting the NF-κB pathway for neuroprotection (2023) [1](https://doi.org/10.1038/s41573-023-00723-4)
sun2018, Non-canonical NF-κB signaling pathway in neurodegeneration (2018)
wajant2003, Tumor necrosis factor signaling (2003) [1](https://doi.org/10.1038/sj.cdd.4401235)
wu2017, TNF receptor-associated factor 2 and ALS: genetic and mechanistic studies (2017)
xu2020, TRAF2 in apoptosis and inflammatory diseases (2020)
yan2020, TRAF2 modulates neuroinflammation through NIK-dependent pathways (2020)
zhang2018, TRAF2-mediated NF-κB activation in dopaminergic neurons (2018)
zhao2021, Ubiquitination and neuroprotection: TRAF2 as a therapeutic target (2021)

Pathway Diagram

The following diagram shows the key molecular relationships involving TRAF2 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

TRAF2 Gene

TRAF2 Gene

Introduction

TRAF2 Gene

Introduction

Gene Overview

Protein Structure and Function

Domain Architecture

Enzymatic Activity

E3 Ubiquitin Ligase Activity

Scaffold Function

Role in Neurodegeneration

Alzheimer's Disease

Amyloid-Beta-Induced Inflammation

Neuronal Survival vs Death

Glial Activation

Tau Pathology

Parkinson's Disease

Dopaminergic Neuron Vulnerability

Microglial Activation

Alpha-Synuclein Pathology

Amyotrophic Lateral Sclerosis (ALS)

Neuroinflammation Mechanisms

Signaling Pathways

Canonical NF-κB Pathway

Non-Canonical NF-κB Pathway

MAPK Pathways

Protein Interactions

Expression Pattern

Clinical Significance

Therapeutic Implications

Challenges

Diagnostic Potential

Research Methods

Experimental Models

Key Techniques

Key Publications

See Also

External Links

References

Pathway Diagram